University of Missouri Participating in Clinical Trials for New COVID-19 Vaccine
The University of Missouri is taking part in clinical trials for a new COVID-19 vaccine.
The University of Missouri School of Medicine said yesterday (Thursday) that it enrolled 103 people in Phase 3 clinical trials and is testing the safety and effectiveness of a coronavirus vaccine developed by the U.S. biotechnology company Novavax.
The participants will randomly receive the vaccine in 2 doses, 21 days apart.
The trials for the Novavax vaccine involve 30,000 people across approximately 115 sites in the United States and Mexico.